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Background: This is an international study across four European countries (Belgium[BE], the Netherlands[NL], Italy
[IT] and Spain[ES]) between 2009 and 2011, describing and comparing care and care setting transitions provided in
the last three months of life of cancer patients, using representative GP networks.
Methods: General practitioners (GPs) of representative networks in each country reported weekly all non-sudden
cancer deaths (+18y) within their practice. GPs reported medical end-of-life care, communication and circumstances
of dying on a standardised questionnaire. Multivariate logistic regressions (BE as a reference category) were
conducted to compare countries.
Results: Of 2,037 identified patients from four countries, four out of five lived at home or with family in their last
year of life. Over 50% of patients had at least one transition in care settings in the last three months of life; one
third of patients in BE, IT and ES had a last week hospital admission and died there. In the last week of life, a
treatment goal was adopted for 80-95% of those having palliation/comfort as their treatment goal. Cross-country
differences in end-of-life care provision included GPs in NL being more involved in palliative care (67%) than in
other countries (35%-49%) (OR 1.9) and end-of-life topics less often discussed in IT or ES. Preference for place of
death was less often expressed in IT and ES (32-34%) than in BE and NL (49-74%). Of all patients, 88-98% were
estimated to have distress from at least one physical symptom in the final week of life.
Conclusion: Although palliative care was the main treatment goal for most cancer patients at the end of life in all
four countries, frequent late hospital admissions and the symptom burden experienced in the last week of life
indicates that further integration of palliative care into oncology care is required in many countries.Background
While survival rates for cancer have increased consider-
ably, it is still one of the leading causes of death in many
developed countries [1,2]. For people suffering from an
advanced form of cancer, palliative care is recognised as
the preferred form of care at the end of life (EOL). The
World Health Organisation (WHO) defines palliative* Correspondence: winne.ko@vub.ac.be
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unless otherwise stated.care as ‘an approach that improves the quality of life of
patients and their families facing the problems associa-
ted with life-threatening illness, through the prevention
and relief of suffering by means of early identification
and impeccable assessment and treatment of pain and
other problems, physical, psychosocial and spiritual’ [3].
Within the framework of palliative care, several topics
are considered important [4], such as the use of pallia-
tive care services, communication, advance care plan-
ning and the circumstances of dying. Palliative care has
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port its delivery [5-7]. However, cross-country population-
based studies aimed at describing these variations in
actually delivered EOL care for people with cancer in
Europe are scarce [4,8,9]. Existing studies are often re-
stricted in the themes covered e.g. pain [10] or place of
death [11] or in terms of the study population e.g. hospital
or hospice settings [12,13].
Comparative and nationwide EU studies measuring
across different care settings and cancer types could in-
form us on organising palliative care for dying cancer
patients. General practitioners (GPs) are highly access-
ible in Europe and they have a central coordinating role
in patient care in most EU countries [14]. GPs can ge-
nerally provide a good public health perspective on end-
of-life care in their own country. In this study, we aim to
use nationwide networks of GPs in four EU countries
(Belgium [BE], the Netherlands [NL], Italy [IT] and
Spain [ES]) to describe and compare the medical care
process, patient-GP communication processes and the
actual circumstances of dying of cancer patients in the
four countries studied.
Methods
Design
Data were collected within the European Sentinel GP
Networks Monitoring End-of-Life Care (EURO SENTI-
MELC) study, which continuously monitored EOL care
via the use of representative networks of GPs in 2009–
2011 in four EU countries: 2009–2010 in Belgium, the
Netherlands and Italy, and 2010–2011 in Spain. All
countries were sampled nationwide except Spain, where
two regions (North: Castilla y León and East: Valencia)
were included.
Both the study protocol and an earlier wave of data
(2008) comparing deceased cancer patients in Belgium
and the Netherlands have been published [4,15,16].
Using a mortality follow-back questionnaire design, GPs
reported all deaths in their practices (age ≥ 18 yrs.) on
the EOL care provided in the final months of life on
standardised forms.
Palliative care in the four countries studied
Access to palliative care has been recognised as a right
in all countries except NLalthough there it is covered by
the national health insurance. In all four countries, some
type of plan or national guideline for palliative care is
available [17]; it is therefore understood that patients in
these countries have access to palliative care. However,
none of these countries recognise palliative care as a
medical specialty and the model of palliative care pro-
vision varies. For example, GPs co-ordinate care in Italy
and Spain in the primary care settings, while in Belgium
the care is often shared in the context of a multidisciplinaryteam and in the Netherlands palliative care is pro-
vided mainly by the GPs in consultation with specia-
list teams [7,17].
Setting and participants
In general the GP networks are representative of all GPs
in the country in terms of age, gender and geographical
distribution. Sentinel surveillance systems of GPs are
used to provide information regarding the whole patient
population in a country, particularly in countries where
general practice is highly accessible. Percentages of the
general population covered by the GP sentinel networks
are 1.75% of the total Belgian population, 0.8% of the
Dutch population, 2.2% in Valencia, 3.5% of the adult
population in Castilla y Leon and 4% of the Italian popu-
lation (per health district). For the specific purpose of
our study we additionally analysed the representativity of
the networks to cover all deaths in the country. These
results were published earlier [16] showing that data col-
lected from the GP networks had significant but small
differences from available mortality statistics or death
certificate studies in terms of age, gender and place of
death [16]. In all countries GPs can identify deaths due
to cancer and non-cancer and those dying at home as
well as in institutional settings. GPs appear to underre-
port a limited number of deaths ie non-sudden hospital
deaths and deaths of people under 65 years in Belgium,
and possibly also sudden hospital deaths in all countries
[16]. Apart from in Italy, the networks in all countries
are existing Sentinel GP networks involved in the sur-
veillance of different health related topics [16]. In 2009,
the number of GPs participating in the study were 199
(1.8%) in Belgium, 59 (0.8%) in the Netherlands and 149
(4.3%) in Italy. In 2010, the figures were 189 (1.5%) in
Belgium, 63 (0.8%) in the Netherlands, 94 (2.7%) in Italy,
and 173 in Spain (114 (3.4%) in Castilla and León, 59
(3%) in Valencia).
For this study, we included cancer patients only i.e.
cancer as GP-reported ‘underlying cause of death’, and
excluded those judged to have died ‘suddenly and totally
unexpectedly’ by the GP. Nursing home deaths from the
Netherlands were excluded since GPs discontinued their
care after the transition to a nursing home where care is
taken over by elderly care physicians.
Data collection and measurements
To minimise recall bias, physicians recorded deaths im-
mediately after the patient died. Paper-based forms were
administered in Belgium, the Netherlands and Castilla y
León, whereas a web-based registration was adopted in
Italy and an electronic registry in Valencia. To ensure
the quality of data collected, instructions on filling out
the form were sent to GPs at the beginning of the year
in all countries. Every GP is asked to fill in a weekly,
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a deceased patient. Where a patient had died during that
week, the GP filled in the questions concerning care and
dying. Only if GPs registered weekly for 26 weeks or
more were their data included in the databases.
GPs answered questions about the final three months of
life of deceased patients. These questions were derived
from and developed in previous research [4,16,18,19,20].
A validated item, the MSAS-GDI, was included in the
questionnaire [21]. Other items in the questionnaire had
been pre-tested in the pilot studies with experts to in-
crease validity and reliability. Further details can be found
in the methodological paper published earlier [16].
Questions were classified into three palliative care do-
mains measuring:
 Medical care processes (last three months
and last week of life): number of GP-patient
contacts, transitions between care settings, use of
specialist palliative care services, use of GP
palliative care, costs and burden of informal
caregivers as judged by the GP, treatment goals
(cure, life-prolonging, palliative care in the final
three months of life), terminal hospital admission
(i.e. dying in the hospital) and timing of this
admission
 Communication processes:1. Patient-GP conversations about primary
diagnosis, incurability of illness, life expectation,
possible medical complications, physical
complaints, psychological problems, social
problems, spiritual problems, options for
palliative care, burden of treatments
(options: yes, no, not applicable)
2. EOL preferences for place of death and medical
treatment as known to the GP. Circumstances of dying in the last week of life
Physical and psychological symptom distress was mea-
sured using the Memorial Symptom Assessment Scale-
Global Distress Index (MSAS-GDI) [21]. GPs estimated:
1. Physical symptom distress: lack of appetite, lack of
energy, pain, drowsiness, constipation, dry mouth,
difficulty in breathing (dyspnoea) (GPs first indicated
the presence of symptoms as yes, no or unknown; if
yes, they indicated not at all, a little bit, somewhat,
quite a bit or very much)
2. Psychological symptom distress: sadness, worry,
irritation, nervousness (GPs first indicated the
presence of symptoms as yes, no or unknown; if yes,they indicated rarely occasionally, frequently, or
almost constantly).
Basic information about the patient (age, gender, type of
malignancy, longest place of residence in the last year and
place of death) was also registered by the GPs. Questions
were first developed in Dutch and subsequently translated
into French and English, and from English to Italian and
Spanish through forward-backward procedures [16].
Ethical approval
In Belgium the protocol of the study was approved by
the Ethical Review Board of Brussels University Hospital
of the Vrije Universiteit Brussel (2004). In Italy, ethics
approval for data collection was obtained from the Local
Ethical Committee ‘Comitato Etico della Azienda U.S.L.
n. 9 di Grosseto’, Tuscany (2008). Ethical approval was
not required for posthumous collection of anonymous
patient data in the Netherlands [22,23] or Spain [24-26].
Patients and GPs remain anonymous to researchers and
the institutes.
Statistical analysis
Descriptive statistics were employed to show the distri-
bution of characteristics of the study population and
Pearson’s chi-squared tests to detect cross-country dif-
ferences (p < .001).
Further multivariate logistic regression analyses (with
Belgium as the reference category) were performed to
study the cross-country variations in EOL care controlling
for differences in place of death, age and sex and, for the
analyses regarding circumstances of dying, we additionally
controlled for the number of GP contacts in the last week
of life. Odds ratios (ORs) and 95% confidence interval
(95% C.I.) were calculated. All analyses were completed
with SPSS20.0 (IBM Corp, Armonk, NY)
Results
Characteristics of patients
A total of 2,037 deceased cancer patients were identified
from four countries (Table 1). Mean age was 73.1 years.
Over 85% of cancer patients lived at home or with family
in their last year of life. In Belgium and the Netherlands,
11% and 9% lived in a care home whereas the figure was
3% in Italy and 4% in Spain.
Home deaths were more common in the Netherlands
(57.9%) and Spain (51.1%).Except for the Netherlands
(17%), more than one third of cancer patients died in hos-
pital in all countries (34%[BE], 38%[IT] and 35%[ES]).
Medical care processes at the end of life
During the last three months of life, GPs had more than
three contacts with patients in 23% (BE), 35% (ES), 42%
(NL) and 58% (IT) of cases (Table 2). In all countries,
Table 1 Characteristics of the study population: non-sudden cancer deaths (N = 2037)
Characteristics Belgium (N = 595) The Netherlands (N = 335) Italy (N = 830) Spain (N = 277) p-valueb
N (%) N (%) N (%) N (%)
Age group .156
18-64 160(27.1) 90(26.9) 195(23.5) 59(21.3)
65-74 131(22.2) 94(28.1) 210(25.3) 65(23.5)
75-84 184(31.2) 103(30.7) 257(31.0) 97(35.0)
85 or above 115(19.5) 48(14.3) 168(20.2) 56(20.2)
Mean 72.5 71.9 73.6 74.2
Gender <.001
M 328(55.1) 177(53.2) 448(54.0) 186(67.6)
F 267(44.9) 156(46.8) 382(46.0) 89(32.4)
Types of malignancy <.001
Lung 148(24.9) 80(25.0) 182(26.5) 53(19.8)
Breast 51(8.6) 33(10.3) 57(8.3) 11(4.1)
Colorectal 69(11.6) 38(11.9) 102(14.8) 49(18.3)
Prostate 25(4.2) 23(7.2) 35(5.1) 29(10.8)
Other 302(50.8) 146(45.6) 312(45.3) 126(47.0)
Longest place of residence in the last year <.001
Home or with family 516(87.2) 300(90.6) 799(96.5) 258(95.2)
Care home 65(11.0) 30(9.1) 21(2.5) 10(3.7)
Other 11(1.9) 1(0.3) 8(1.0) 3(1.1)
Place of death <.001
Home 196(33.2) 194(57.9) 377(45.5) 139(51.1)
Nursinghome/Residential home for older people 71(12.0) 28(8.4) 41(5.0) 11(4.0)
Hospital 198(33.5) 58(17.3) 312(37.7) 95(34.9)
Palliative Care Unit/Hospice 122(20.6) 54(16.1) 94(11.4) 26(9.6)
Elsewhere 4(0.7) 1(0.3) 4(0.5) 1(0.4)
aMissing for age group: n = 5, gender: n = 4, Type of malignancy: n = 166, Longest place of residence last year: n = 15, Place of death: n = 11.
bχ2test on cross-country differences.
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69%) had at least one transition between care settings in
their last three months of life. Specialist palliative care
services were used in 37% of cases in NL, compared with
58%, 62% and 65% in ES, IT and BE respectively. GP pal-
liative care was provided until death in 67% of cases in
NL, compared with 49%, 44% and 35% in ES, BE and IT.
Five percent of patients in Spain had difficulty in co-
vering costs, differing from 20%, 38% and 43% in BE, NL
and IT. From 31% in NL to 35% (BE), 42% (ES) and 78%
(IT) of informal caregivers in the four countries were
perceived to be overburdened.
In the last week of life, GPs had more than one con-
tact with patients in two thirds of cases in all countries
and 17% [NL] to 27% [ES] of patients were transferred
to another setting. Terminal hospital admission was
experienced by one in three patients in BE, IT and ES
respectively, and by 17% in NL. These admissions oc-
curred in the last week of life in one out of three casesexcept in ES where it was 48%. For all countries, pallia-
tive care was the main treatment aim for most patients
in the last week of life (about 90% of patients in BE, NL
and ES, and 80% in IT).
After controlling for differences in patient characteris-
tics, variations in GP contacts in the last three months
of life remained significant, as did the use of GP and
specialist palliative care services.
Communication processes at the end of life
In all countries, a large majority of GPs had discussed
one or more topics (between 89% [IT] and 98% [NL])
(Table 3). Most GPs in NL (95%) discussed primary diag-
nosis with patients, compared with84%, 71% and 66%
respectively in BE, ES and IT. Physical complaints were
also frequently discussed (between 83% [IT] and 96%
[NL]). Over half of patients had conversations with GPs
on psychological problems (between 60% [IT] and 87%
[NL]). One out of three patients talked about social
Table 2 Characteristics of the medical care processes at the end of life
Belgium
(N = 595)
The Netherlands
(N = 335)
Italy (N = 830) Spain (N = 277) p-valuea
Characteristics N (%) N (%) ORb (95% C.I.) N (%) ORb (95% C.I.) N (%) ORb (95% C.I.)
During the last three months of life:
More than three GP-patient contactsd 137(23.0) 140(41.8) 2.2(1.6-3.0) 480(57.8) 4.6(3.6-5.9) 98(35.4) 1.7(1.3-2.4) <.001
At least one transition to another
care setting
407(69.0) 173(52.6) 0.8(0.6-1.2) 534(64.4) 0.9(0.7-1.3) 156(57.4) 0.7(0.5-1.1) <.001
Specialist palliative care services
initiated
370(65.1) 119(37.0) 0.2(0.2-0.3) 502(62.7) 1.2(0.9-1.6) 160(57.8) 1.0(0.7-1.4) <.001
GP provided palliative care until death 262(44.0) 219(67.0) 1.9(1.3-2.7) 290(35.0) 0.4(0.3-0.6) 129(49.4) 0.8(0.5-1.2) <.001
Difficult in covering care costs 92(20.3) 107(38.4) 2.5(1.8-3.6) 306(42.5) 3.0(2.3-4.1) 11(4.9) 0.2(0.1-0.4) <.001
Informal caregivers feeling overburdened 183(34.9) 92(30.9) 0.7(0.5-1.00) 590(77.9) 6.1(4.7-8.0) 99(41.8) 1.1(0.8-1.6) <.001
Palliation as important treatment goal
(v curative/prolonging life)
305(58.1) 223(76.4) 2.2(1.6-3.1) 418(60.9) 1.2(0.9-1.5) 138(63.3) 1.2(0.9-1.8) <.001
During the last week of life:
One or more GP-patient contacts 448(75.3) 286(85.4) 1.3(0.9-1.9) 625(75.3) 0.8(0.6-1.1) 178(64.3) 0.4(0.3-0.6) <.001
At least one transition to another
care setting
145(24.7) 56(16.8) 0.9(0.6-1.3) 159(19.5) 0.8(0.6-1.1) 71(27.4) 1.5(1.1-2.3) 0.002
Terminal hospital admission 198(33.5) 58(17.3) 0.4(0.3-0.6) 312(37.7) 1.2(1.0-1.5)c 95(34.9) 1.1(0.8-1.6) <.001
Admission during last week
(vbefore last week)e
70(35.7) 22(38.6) 1.2(0.6-2.2) 100(33.2) 1.0(0.6-1.4) 44(47.8) 1.8(1.1-3.1) .084
Palliation as important treatment goal
(v curative/prolonging life)
522(91.9) 296(94.9) 1.4(0.8-2.6) 487(80.0) 0.4(0.3-0.6) 206(89.6) 0.9(0.5-1.5) <.001
Abbreviations: GP general practitioner, OR odds ratio.
Missing data:
During last 3 months of life: more than three GP-patient contacts: n = 1%; at least one transition: n < 1%; specialist palliative care initiated: n < 4%; GPs’ provision
of pall care until death: n < 3%; difficult in covering care costs: n < 18%; informal caregivers feeling overburdened: n < 11%.
During last week of life: transferred at least once: n < 3%; terminal hospital admission: n < 1%; admission during last week:n < 68%, palliation as important
treatment goal during last week: n < 16%.
aχ2test on cross-country differences.
bOdd Ratios from multivariate logistic regression models. For these analyses, we compared end-of-life care between patients with cancer in the four countries,
with Belgium as the reference category, and adjusted differences in place of death, age, gender and the types of malignancy. Odds ratios in bold are statistically
significant at p < 0.05.
cPlace of death not controlled for in multivariate analyses.
dmedian number of contacts during the last three months of lifeacross countries was 3.
eFor patients who died in hospitals.
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pared with 57% and 70% in BE and NL respectively.
‘Spiritual problems’was the topic least often discussed in
all countries, from about 15% in IT and ES to 32% in BE
and slightly over half (54%) in NL. Except in IT (37%),
over two-thirds of GPs in all countries had conversations
on the options of palliative care (from 67% [ES] to 70%
[BE] and 88% [NL]).
Other than in NL (74%), fewer than half of cancer pa-
tients expressed a preference for place of death (between
32% [IT] and 49% [BE]). Fewer than one-fifth of patients
in ES (14%) and IT (18%) indicated at any time a prefe-
rence about medical treatment, whereas the figures were
41% and 65% in BE and NL.
When other factors were controlled for, seven out of
10 of the aforementioned differences remained signifi-
cant and topics such as the incurability of illness (more
in NL, 5.0; less in IT &ES, 0.3) and options for palliative
care (more in NL, 1.6; less in IT, 0.4) were less oftendiscussed in IT and ES than in BE and the NL. The
higher frequencies of discussions in NL on preference
for place of death (OR 2.3, less in IT & ES, 0.4) and
medical treatment (OR 2.4, less in IT 0.3 and ES 0.2)
remained.
Circumstances of dying in the last week of life (Table 4)
Suffering from physical symptoms was common among
cancer patients; from 88% (IT) to 92% (BE & NL) and 99%
(ES) experienced at least one symptom. Over 70% of the
patients in all countries experienced lack of energy, except
in ES (57%). From 64%, 87% to 100% of patients in re-
spectively in BE, IT and ES were judged to be distressed
by at least one psychological symptom, and the figure was
48% for NL. Respectively 66% [IT], 75% [BE], 79% [SP] and
87% [NL] of patients in all countries died in their preferred
place if their wishes were known to the GP.
Results from multivariate analyses confirmed cross-
country differences on symptoms including pain (more
Table 3 Characteristics of communication processes at the end of life
Belgium
(N = 595)
The Netherlands
(N = 335)
Italy (N = 830) Spain (N = 277) p-valuea
Characteristics N (%) N (%) OR
(95% C.I.)
N (%) ORb
(95% C.I.)
N(%) ORb
(95% C.I.)
GP-patient conversations about:
Primary diagnosis 474(84.2) 303(95.0) 3.1(1.8-5.4) 505(66.4) 0.3(0.3-0.5) 157(70.7) 0.4(0.3-0.6) <.001
Incurability of illness 416(74.4) 298(94.6) 5.0(2.9-8.6) 345(46.2) 0.3(0.2-0.4) 95(45.0) 0.3(0.2-0.4) <.001
Life expectation 363(64.5) 282(89.5) 4.1(2.7-6.2) 277(37.0) 0.3(0.2-0.4) 56(27.1) 0.2(0.1-0.3) <.001
Possible medical complications 393(70.1) 267(86.4) 2.6(1.8-3.9) 441(58.7) 0.6(0.4-0.7) 137(62.8) 0.7(0.5-0.95) <.001
Physical complaints 514(90.7) 306(95.9) 2.3(1.2-4.4) 632(83.0) 0.5(0.4-0.7) 208(90.4) 0.9(0.5-1.6) <.001
Psychological problems 416(74.3) 272(86.9) 2.1(1.4-3.1) 442(59.1) 0.5(0.4-0.7) 146(66.2) 0.7(0.5-0.9) <.001
Social problems 284(56.5) 202(70.1) 1.8(1.3-2.6) 249(34.5) 0.4(0.3-0.5) 63(34.4) 0.4(0.3-0.6) <.001
Spiritual problems 169(32.4) 156(54.4) 2.1(1.5-2.9) 104(14.4) 0.3(0.3-0.5) 27(14.7) 0.3(0.2-0.5) <.001
Options for palliative care 389(70.0) 272(88.0) 2.7(1.8-4.0) 267(36.4) 0.2(0.2-0.3) 138(66.7) 0.8(0.5-1.1) <.001
Burden of treatments 397(72.6) 244(81.6) 1.6(1.1-2.3) 367(50.0) 0.4(0.3-0.5) 136(68.3) 0.8(0.5-1.1) <.001
Overall: One or more of these topics was discussed 447(94.1) 259(97.7) 2.2(0.9-5.4) 586(88.7) 0.5(0.3-0.7) 133(95.7) 1.2(0.5-2.9) <.001
End-of-lifepreferences----Patient everexpressed a preference:
For place of death 293(49.3) 245(73.8) 2.3(1.7-3.1) 267(32.2) 0.4(0.3-0.5) 85(34.0) 0.4(0.3-0.6) <.001
About a medical treatment 225(40.5) 198(65.1) 2.4(1.7-3.2) 118(18.2) 0.3(0.3-0.4) 29(14.3) 0.2(0.1-0.4) <.001
Missing data:
Prior to last month: Diagnosis, possible medical complication, psychosocial problems: n < 10%; incurability of illness, life expectancy: n < 11%; physical problems:
n < 8%, social problems; n < 17%; spiritual problems, n < 16%; options of palliative care, n < 12%; Burden of treatment: n < 13%; one or more issues
discussed: n < 23%.
Preference for place of death: n < 13%; preference about medical treatment: n < 17%.
aχ2test on cross-country differences.
bOdds ratios from multivariate logistic regression models. For these analyses, we compared end-of-life care between patients with cancer in the four countries,
with Belgium as the reference category, and adjusted differences in place of death, age, gender and the types of malignancy. Odds ratios in bold are statistically
significant at p < 0.05.
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ES [2.3]) and, feeling sad (more in IT [2.6] & ES [3.4]).
Patients in NL were more likely (OR 1.8) and patients in
IT (0.6) less likely to die in their preferred location com-
pared with BE.
Discussion
Overall In all countries, four-fifths of cancer patients
lived at home or with family in their last year of life.
However, the study shows that transitions between care
settings at the end of life are common in all countries
i.e. more than half over the last three months of life and
between 17-27% in the last week of life, and one third of
patients (except in NL) died in hospital. There was also
a substantial amount of cross-country variation in the
provision of end-of-life care to cancer patients even
though 80-95% had palliative care as an important treat-
ment goal in their last week of life. While GPs were
more strongly involved in palliative care in NL than in
other countries, specialist palliative care services were
used less often. End-of-life topics were less often dis-
cussed and preference for place of death was less often
known by the GPs in IT and ES compared with BE and
NL. More than 88% of all patients in all countries wereestimated to have distress from at least one physical symp-
tom in the final week of life and more than half of cancer
patients from at least one psychological symptom.
Strengths and weaknesses
Strengths of the study include the administration of an
analogous research design across countries and the
weekly registration keeping recall bias limited, resulting
in a robust four-country database of deaths, comparing
actual end-of-life care practices. This information sup-
plements the existing data from death certificates or
cancer registries [27], hence can serve as an important
basis for organisational planning. However, some limi-
tations should be noted. Selecting GPs as the source of
information implies underestimation of certain types of
care is possible. Nursing homes were excluded in the
Netherlands, therefore elderly cancer patients might be
underrepresented, although Dutch nursing homes are
mainly occupied by people with neurodegenerative dis-
orders [28]. Variations in medical practices exist across
countries [29] and the quality of specialist palliative care
services was not measured. Also, the questionnaire was
kept short and further details on care provision were not
available. Even though GPs could offer a macro view of
Table 4 Circumstances of the dying process
Belgium
(N = 595)
The Netherlands
(N = 335)
Italy (N = 830) Spain (N = 277) p-valuea
Variable N(%) N(%) ORb
(95% C.I.)
N(%) ORb
(95% C.I.)
N(%) ORb
(95% C.I.)
Physical symptom distress in last week of life
GP could make estimationc 520(87.4) 285(85.1) 0.2(0.1-0.3) 702(84.6) 0.5(0.4-0.8) 231(83.4) 0.8(0.5-1.3) .355
Distress from at least one physical symptom 412(91.6) 215(91.9) 1.1(0.6-1.9) 571(88.4) 0.7(0.4-1.1) 134(98.5) 5.8(1.4-24.8) .002
Lack of appetite 280(60.1) 120(49.6) 0.7(0.5-1.0) 299(47.8) 0.6(0.4-0.8) 67(49.6) 0.7(0.4-0.992) .001
Lack of energy 344(72.0) 186(73.5) 1.1(0.8-1.7) 482(73.8) 1.0(0.8-1.3) 83(56.8) 0.5(0.3-0.8) .001
Pain 93(23.7) 56(26.8) 1.4(0.9-2.2) 236(38.2) 2.0(1.5-2.8) 46(48.4) 3.2(2.0-5.2) <.001
Feeling drowsy 142(32.9) 60(29.0) 1.0(0.7-1.5) 182(29.4) 0.9(0.7-1.2) 18(25.0) 0.6(0.3-1.1) .438
Constipation 57(17.8) 22(13.8) 0.7(0.4-1.3) 158(27.7) 1.7(1.2-2.4) 26(32.1) 2.1(1.2-3.8) <.001
Dry mouth 73(20.4) 44(22.6) 1.1(0.7-1.7) 177(30.9) 1.6(1.1-2.2) 34(39.5) 2.3(1.3-3.8) <.001
Difficulty breathing 140(36.2) 58(32.8) 1.1(0.7-1.6) 243(40.6) 1.3(1.0-1.8) 40(60.6) 2.5(1.4-4.4) <.001
Psychological symptom distress in last week of life
GP could make estimationc 487(81.8) 258(77.0) 0.2(0.1-0.3) 649(78.2) 0.6(0.3-1.1) 208(75.1) 0.7(0.5-1.1) 0.096
Distress from at least one psychological symptom 241(63.9) 75(48.4) 0.5(0.4-0.8) 341(87.2) 4.2(2.8-6.3) 90(100) Notestim. <.001
Feeling sad 143(38.0) 42(25.1) 0.7(0.4-1.0) 247(58.9) 2.6(1.9-3.6) 57(67.1) 3.4(2.0-5.8) <.001
Worrying 162(41.9) 50(29.9) 0.7(0.4-1.0) 164(41.7) 1.0(0.7-1.3) 54(63.5) 2.2(1.3-3.7) <.001
Feeling irritable 87(25.9) 11(8.7) 0.3(0.1-0.6) 145(42.0) 2.1(1.5-3.0) 18(54.5) 3.5(1.6-7.5) <.001
Feeling nervous 116(33.0) 16(11.8) 0.3(0.2-0.5) 146(42.6) 1.6(1.2-2.3) 22(46.8) 1.7(0.9-3.3) <.001
Died at the place of wishd 221(75.4) 214(87.3) 1.8(1.1-2.9) 176(65.9) 0.6(0.4-0.8) 67(78.8) 1.2(0.6-2.1) <.001
Missing data:
Physical symptoms were measured on five levels in the original questionnaire (not at all, a little bit, somewhat, quite a bit or very much), variables were later
recoded into two categories: quite a bit and very much vs all others; Missing values for physical symptoms Distress from at least one physical symptom: n < 29%;
Physical symptoms: lack of appetite: n < 28%; lack of energy: n < 26%; pain: n < 17%; drowsy: n < 19%; constipation: n < 21%; dry mouth: n < 22%; difficulty
breathing: n < 19%.
Psychological symptoms were measured on four levels in the original questionnaire (rarely, occasionally, frequently or almost constantly), variables were later
recoded into two categories: frequently and almost constantlyvs all others; Distress from at least one psychosocial symptom: n < 51%; Psychosocial symptoms:
feeling sad: n < 49%, worry: n < 50%, irritable: n < 59%, nervous: n < 57%.
Died at the preferred place of wish: information available for 44% of the patients.
aχ2test on cross-country differences.
bFrom multivariate logistic regression models. For these analyses, we compared end-of-life care between patients with cancer in the four countries, with Belgium
as the reference category, and adjusted differences in place of death, age, gender, types of malignancy and the number of GPs contact in the last week of life.
Odds ratios in bold are statistically significant at p < 0.05.
cFor at least one symptom.
dIf the wish of the patient was known to the GP. For the death at the place of wish, we adjusted differences in the longest place of residence, number of GPs
contact in the last week of life, age, sex and types of malignancy.
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http://www.biomedcentral.com/1471-2407/14/960the end-of-life care received by their patients, caregiver-
reported outcomes might be more accurate for some
items such as caregiver burden and patients’ psycho-
logical symptoms in the last week of life. Currently these
items were based on ‘GPs’ perception’ after death, and
therefore should be interpreted with caution as GPs
might under/over-estimate the burden of care.
Common challenges in end-of-life care
One important common challenge concerns transitions
between care settings, which were common during both
the final three months (more than half in all countries)
and the last week (between one in six and one in four
cases) of life. A considerable number of patients (from a
third to half ) continued to be admitted to hospital in the
last week of life and eventually died there. One third ormore of informal caregivers of cancer patients were per-
ceived as being overburdened (between 31% and 79%).
Transitions between care settings and terminal hos-
pital admissions are incongruent with the wishes of most
patients to die in familiar surroundings and may not
only adversely affect the quality of care and the quality
of dying of the patient [30-33] but also influence the
quality of life of informal caregivers [34,35]. Although it
is unclear from our study why these transitions took
place, the results do show that all countries, though the
Netherlands least, are struggling to meet most cancer
patients’ preferences for dying at home, often due to late
hospital admissions. While most palliative care policies
of EU countries advocate avoiding hospital death, these
results call for the need to understand how this goal can
be attained.
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end-of-life communication
Palliative care is organised differently in each of the four
countries [7] and our results demonstrate large variations
in the care delivered in the final three months. The
Netherlands showed a lower percentage of specialist pal-
liative care provision (one third vs. half or more in the
other countries) and a stronger GP role in providing end-
of-life care for cancer patients. In other countries, the role
of specialist palliative care services in counselling regular
caregivers is more pronounced in the final months of life.
The emphasis on GPs being the primary palliative care
providers in the Netherlands [36,37] –noticeably in educa-
tion and policy – might be a possible explanation for this
difference. Existing research showed that in some cases
the involvement of specialist palliative care [38] might in-
crease the proportions of home death, but this cannot be
verified by our existing data. These differences might also
be related to cultural, legal, societal and organisational
variations in care [39-41]. Future studies need to shed
light on the interplay between these factors to explain the
variations we found.
GPs in the four countries engaged in conversations with
their patients concerning prognosis, spiritual issues, pal-
liative care and other end-of-life care issues to various de-
grees. This illustrates the huge variations in the topics
discussed at the end of life in Europe corresponding with
results found in previous studies in several other popula-
tions [17,42]. While in all countries physical complaints
were frequently discussed, in some such as Belgium and
the Netherlands incurability of illness and life expectation
were also often discussed, which was not the case in Italy
or Spain. Though standardisation in communication might
not be feasible due to factors like cultural differences, it
would be enlightening to find out how GPs in Belgium and
the Netherlands approached patients in these difficult con-
versations [4], for example whether communication guides
could increase physician/patient communication [43,44].
Furthermore, while all the four countries we studied af-
firm palliative care as a right for all patients, due to the
differences in existing healthcare systems the content of
care differs across the countries. Though the present study
could not provide answers about the quality of care re-
ceived by patients in these countries e.g. satisfaction of
family, cost and benefit analyses, differences found in out-
comes such as place of death and the number of contacts
with patients in the last week of life might reflect the spe-
cifics of palliative care organisation, such as strong pri-
mary care in the Netherlands and the more frequent use
of specialist palliative care in Belgium.
Circumstances of dying
Although the results concerning symptoms in the last
week of life should be interpreted with caution consideringthat they were rated by GPs rated the symptoms in all
countries GPs indicated that there is a high prevalence of
symptom distress in the last week of life. This might reflect
a common problem of symptom control in all countries.
On the other hand, the proportions of missing values for
physical and psychological symptoms were higher than
other items in the questionnaire, which might reflect the
limitation of using GPs in reporting them. Symptoms and
distress levels reported by patients themselves are more
accurate than those rated by proxies, including GPs,
nurses or families. The present study did not include pa-
tients reported symptom burden (reporting could be bur-
densome at the end of life) and thus the results canonly be
interpreted as what had been perceived by the caring GPs
in the final months of life.
Implications for practice, policy and future research
The latest EAPC Atlas for Palliative Care [7] brings en-
couraging news to by illustrating recent changes such as
the development of postgraduate courses in Belgian
universities, the updated Dutch palliative care guidelines,
the growth of palliative care support teams in Italy and a
Spanish law (applicable in three regions) affirming citizens’
rights to palliative care. Nevertheless, our results revealed
that hospitalisations and transitions remain frequent. A lot
of cancer patients also had a number of burdensome
symptoms at the end of life according to their GPs, which
suggests the need for the support of clinicians in assessing
the distress of patients. Also, several country-differences
became apparent such as in communications and types of
palliative care delivery. National palliative care organisa-
tions may wish to consider adjusted policies or guidelines
for GPs to improve their skills in end-of-life communica-
tions and countries could benefit from learning from each
other to improve care.
Conclusion
Although palliative care was the main treatment goal for
most cancer patients at the end of life in all four coun-
tries, frequent late hospital admissions and the symptom
burden experienced in the last week of life indicates that
further integration of palliative care into oncology care
is required in many countries.
Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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